Adobe Stock - whitehoune Paris-based drug delivery specialist Ceres Brain Therapeutics SA has raised €6m led by ANJAC, a French family-owned industrial group and preferred partner of healthcare laboratories and beauty and well-being brands, to support the clinical development neurological treatments.
Arctic TherapeuticsIceland’s Arctic Therapeutics has secured €26.5m in a Series A financing aimed to push its oral drug candidates AT-O01 and AT-004 into clinical trails in patients with rare amyloid aggregation diseases including Alzheimer’s disease.
EU ParliamentEuropaBio calls for an ambitious cross-sectoral EU Biotech Act, that strengthens Europe as a global biotechnology leader for competitiveness and strategic autonomy.
adobe stock.com - HomuGallery The Safety Committee PRAC of the European Medicines Agency EMA is investigating a new potential adverse reaction to the appetite suppressant semaglutide. Epidemiological studies indicate that the rare eye disease non-arteritic anterior ischaemic optic neuropathy (NAION), which leads to blindness, could occur more frequently after treatment with the GLP-1 receptor agonist.
InflaRx Jena-based InflaRx has reached a significant milestone with the European Commission’s approval of GOHIBIC (Vilobelimab), a novel anti-C5a monoclonal antibody for the treatment of SARS-CoV-2-induced Acute Respiratory Distress Syndrome (ARDS).
David_SMC from PixabaySynairgen plc (SNG) has announced the successful completion of a £18m funding round, primarily supported by TFG Asset Management. The funding will advance the Phase 2 INVENT trial, assessing SNG001, an inhaled formulation of the antiviral protein interferon beta, in mechanically ventilated patients with severe viral lung infections.
By Vaccinationist - PubChem, WikipediaJohnson & Johnson has announced the acquisition of biopharmaceutical company Intra-Cellular Therapies, strengthening its position in the market for central nervous system disorder treatments. The $14.6 billion deal involves J&J paying $132 per share, representing a 39% premium over Intra-Cellular’s last closing price.
robin_24, WikipediaLeyden Labs has raised $70 million in a funding round led by ClavystBio and Polaris Partners, boosting its efforts to develop intranasal antibody therapies targeting respiratory viruses, including influenza and coronaviruses.
The Paul Ehrlich Institute (PEI) has approved expansion of the global INVISE Phase 1 clinical trial to Europe. The study aims to evaluate first-in-class gene therapy for the treatment of B-cell malignancies.
Image by Pete Linforth from Pixabay.Angelini Ventures, the corporate venture capital arm of Angelini Industries, focused on investing in early-stage companies in BioTech and Digital Health, co-leads €20m Series A funding round in Neumirna Therapeutics, accelerating next-generation RNA therapeutics for epilepsy and neurological diseases.